tetano
Editor, Senior Moderator
Front Immunol
. 2024 Oct 7:15:1468760.
doi: 10.3389/fimmu.2024.1468760. eCollection 2024. Analysis of B-cell receptor repertoire to evaluate the immunogenicity of SARS-CoV-2 RBD mRNA vaccine: MAFB-7256a (DS-5670d)
Goh Ohji[SUP] #[/SUP][SUP] 1 [/SUP], Yohei Funakoshi[SUP] #[/SUP][SUP] 2 [/SUP], Kimikazu Yakushijin[SUP] #[/SUP][SUP] 2 [/SUP], Takaji Matsutani[SUP] 3 [/SUP], Tomoki Sasaki[SUP] 4 [/SUP], Takahiro Kusakabe[SUP] 5 [/SUP], Sakuya Matsumoto[SUP] 2 [/SUP], Taiji Koyama[SUP] 2 [/SUP], Yoshiaki Nagatani[SUP] 2 [/SUP], Keiji Kurata[SUP] 2 [/SUP], Shiro Kimbara[SUP] 2 [/SUP], Naomi Kiyota[SUP] 2 6 [/SUP], Hironobu Minami[SUP] 2 6 [/SUP]
Affiliations
A monovalent Omicron XBB.1.5 mRNA RBD analogue vaccine, MAFB-7256a (DS-5670d), was newly developed and approved in Japan in the Spring of 2024 for the prevention of COVID-19. However, clinical efficacy data for this vaccine are currently lacking. We previously established the Quantification of Antigen-specific Antibody Sequence (QASAS) method to assess the response to SARS-CoV-2 vaccination at the mRNA level using B-cell receptor (BCR) repertoire assays and the Coronavirus Antibody Database (CoV-AbDab). Here, we used this method to evaluate the immunogenicity of MAFB-7256a. We analyzed repeated blood samples using the QASAS method from three healthy volunteers before and after MAFB-7256a vaccination. BCR response increased rapidly one week post-vaccination and then decreased, as with conventional vaccine. Notably, the matched sequences after MAFB-7256a vaccination specifically bound to the receptor-binding domain (RBD), with no sequences binding to other epitopes. These results validate that MAFB-7256a is an effective vaccine that exclusively induces antibodies specific for the RBD, demonstrating its targeted immunogenic effect.
Keywords: B-cell receptor repertoire; SARS-CoV-2; coronavirus antibody database; mRNA RBD vaccine; quantification of antigen-specific antibody sequence.
. 2024 Oct 7:15:1468760.
doi: 10.3389/fimmu.2024.1468760. eCollection 2024. Analysis of B-cell receptor repertoire to evaluate the immunogenicity of SARS-CoV-2 RBD mRNA vaccine: MAFB-7256a (DS-5670d)
Goh Ohji[SUP] #[/SUP][SUP] 1 [/SUP], Yohei Funakoshi[SUP] #[/SUP][SUP] 2 [/SUP], Kimikazu Yakushijin[SUP] #[/SUP][SUP] 2 [/SUP], Takaji Matsutani[SUP] 3 [/SUP], Tomoki Sasaki[SUP] 4 [/SUP], Takahiro Kusakabe[SUP] 5 [/SUP], Sakuya Matsumoto[SUP] 2 [/SUP], Taiji Koyama[SUP] 2 [/SUP], Yoshiaki Nagatani[SUP] 2 [/SUP], Keiji Kurata[SUP] 2 [/SUP], Shiro Kimbara[SUP] 2 [/SUP], Naomi Kiyota[SUP] 2 6 [/SUP], Hironobu Minami[SUP] 2 6 [/SUP]
Affiliations
- PMID: 39434885
- PMCID: PMC11491357
- DOI: 10.3389/fimmu.2024.1468760
A monovalent Omicron XBB.1.5 mRNA RBD analogue vaccine, MAFB-7256a (DS-5670d), was newly developed and approved in Japan in the Spring of 2024 for the prevention of COVID-19. However, clinical efficacy data for this vaccine are currently lacking. We previously established the Quantification of Antigen-specific Antibody Sequence (QASAS) method to assess the response to SARS-CoV-2 vaccination at the mRNA level using B-cell receptor (BCR) repertoire assays and the Coronavirus Antibody Database (CoV-AbDab). Here, we used this method to evaluate the immunogenicity of MAFB-7256a. We analyzed repeated blood samples using the QASAS method from three healthy volunteers before and after MAFB-7256a vaccination. BCR response increased rapidly one week post-vaccination and then decreased, as with conventional vaccine. Notably, the matched sequences after MAFB-7256a vaccination specifically bound to the receptor-binding domain (RBD), with no sequences binding to other epitopes. These results validate that MAFB-7256a is an effective vaccine that exclusively induces antibodies specific for the RBD, demonstrating its targeted immunogenic effect.
Keywords: B-cell receptor repertoire; SARS-CoV-2; coronavirus antibody database; mRNA RBD vaccine; quantification of antigen-specific antibody sequence.